Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oseltamivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir SCHEMBL19513553 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL4234896 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL32035 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14283136 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL14775954 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL125557 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL13459830 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL18379765 | 0.99 | MEN1 (0.88) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL9281280 | 0.98 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 | |
| Oseltamivir SCHEMBL28299858 | 0.98 | MEN1 (0.86) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111875516-B | Oseltamivir carboxylate and preparation method of atomization agent thereof | 上海爱科百发生物医药技术股份有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-113866337-B | Mass analysis method for separating and measuring oseltamivir phosphate isomer | 哈药集团技术中心 | 2024-03-08 | — | — | CN | disclosed |
| CN-116457058-A | Methods and compositions for treating coronaviruses | 诺沃库勒有限责任公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-111875516-B | Oseltamivir carboxylate and preparation method of atomization agent thereof | 上海爱科百发生物医药技术股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-115529815-A | Pharmaceutical composition of oseltamivir or pharmaceutically acceptable salt thereof for rectal administration, preparation method and application thereof | 广州共禾医药科技有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-114409623-A | Method for preparing baroxavir intermediate | 和鼎（南京）医药技术有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-112159380-B | Process for preparing Barosavir intermediates | 和鼎（南京）医药技术有限公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-113866337-A | Mass analysis method for separating and determining oseltamivir phosphate isomers | 哈药集团技术中心 | 2021-12-31 | — | — | CN | disclosed |
| CN-113527119-A | Preparation method of Barosavir intermediate | 和鼎（南京）医药技术有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-112062750-B | Process for preparing a Barosavir intermediate and intermediate obtained by this process | 和鼎（南京）医药技术有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-107056636-B | Oseltamivir derivative and preparation method and application thereof | 山东大学 | 2021-05-11 | — | — | CN | disclosed |
| CN-108299246-B | Compound and preparation method and application thereof | 江苏康缘药业股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-112159380-A | Process for preparing Barosavir intermediates | 和鼎（南京）医药技术有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-112062750-A | Process for preparing a Barosavir intermediate and intermediate obtained by this process | 和鼎（南京）医药技术有限公司 | 2020-12-11 | — | — | CN | disclosed |